Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand?
Abstract
:1. Introduction
2. Review of Literature
2.1. Methods
2.2. SARS-CoV-2 Vaccines
2.3. Immunological Response to SARS-CoV-2 Vaccines in IBD Patients
2.4. Meta-Analysis of Seroconversion Rates in IBD Patients
2.5. Effectiveness of SARS-CoV-2 Vaccination in IBD Patients
2.6. Safety of SARS-CoV-2 Vaccination in IBD Patients
3. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- Torres, J.; Mehandru, S.; Colombel, J.F.; Peyrin-Biroulet, L. Crohn’s disease. Lancet 2017, 389, 1741–1755. [Google Scholar] [CrossRef]
- Ungaro, R.; Mehandru, S.; Allen, P.B.; Peyrin-Biroulet, L.; Colombel, J.F. Ulcerative colitis. Lancet 2017, 389, 1756–1770. [Google Scholar] [CrossRef]
- Beaugerie, L.; Rahier, J.F.; Kirchgesner, J. Predicting, Preventing, and Managing Treatment-Related Complications in Patients with Inflammatory Bowel Diseases. Clin. Gastroenterol. Hepatol. 2020, 18, 1324–1335.e2. [Google Scholar] [CrossRef] [PubMed]
- Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 2020, 5, 536–544. [Google Scholar] [CrossRef] [Green Version]
- Cummings, M.J.; Baldwin, M.R.; Abrams, D.; Jacobson, S.D.; Meyer, B.J.; Balough, E.M.; Aaron, J.G.; Claassen, J.; Rabbani, L.E.; Hastie, J.; et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: A prospective cohort study. Lancet 2020, 395, 1763–1770. [Google Scholar] [CrossRef]
- Jose, R.J.; Manuel, A. COVID-19 cytokine storm: The interplay between inflammation and coagulation. Lancet Respir. Med. 2020, 8, e46–e47. [Google Scholar] [CrossRef]
- Kessel, C.; Vollenberg, R.; Masjosthusmann, K.; Hinze, C.; Wittkowski, H.; Debaugnies, F.; Nagant, C.; Corazza, F.; Vely, F.; Kaplanski, G.; et al. Discrimination of COVID-19 From Inflammation-Induced Cytokine Storm Syndromes Using Disease-Related Blood Biomarkers. Arthritis Rheumatol. 2021, 73, 1791–1799. [Google Scholar] [CrossRef]
- Singh, A.K.; Jena, A.; Kumar, M.P.; Sharma, V.; Sebastian, S. Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: A systematic review and meta-analysis. United Eur. Gastroenterol. J. 2021, 9, 159–176. [Google Scholar] [CrossRef]
- Group, R.C. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet 2021, 397, 1637–1645. [Google Scholar] [CrossRef]
- Group, R.C.; Horby, P.; Lim, W.S.; Emberson, J.R.; Mafham, M.; Bell, J.L.; Linsell, L.; Staplin, N.; Brightling, C.; Ustianowski, A.; et al. Dexamethasone in Hospitalized Patients with Covid-19. N. Engl. J. Med. 2021, 384, 693–704. [Google Scholar] [CrossRef]
- Gupta, S.; Leaf, D.E. Tocilizumab in COVID-19: Some clarity amid controversy. Lancet 2021, 397, 1599–1601. [Google Scholar] [CrossRef]
- Gavriatopoulou, M.; Ntanasis-Stathopoulos, I.; Korompoki, E.; Fotiou, D.; Migkou, M.; Tzanninis, I.G.; Psaltopoulou, T.; Kastritis, E.; Terpos, E.; Dimopoulos, M.A. Emerging treatment strategies for COVID-19 infection. Clin. Exp. Med. 2021, 21, 167–179. [Google Scholar] [CrossRef]
- Grasselli, G.; Greco, M.; Zanella, A.; Albano, G.; Antonelli, M.; Bellani, G.; Bonanomi, E.; Cabrini, L.; Carlesso, E.; Castelli, G.; et al. Risk Factors Associated with Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Intern. Med. 2020, 180, 1345–1355. [Google Scholar] [CrossRef] [PubMed]
- Chanchlani, N.; Lin, S.; Chee, D.; Hamilton, B.; Nice, R.; Zehra, A.; Bewshea, C.; Cipriano, B.; Derikx, L.; Dunlop, A.; et al. Adalimumab and infliximab impair SARS-CoV-2 antibody responses: Results from a therapeutic drug monitoring study in 11422 biologic-treated patients. J. Crohn Colitis 2021, jjab153. [Google Scholar] [CrossRef] [PubMed]
- Baden, L.R.; El Sahly, H.M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S.A.; Rouphael, N.; Creech, C.B.; et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021, 384, 403–416. [Google Scholar] [CrossRef] [PubMed]
- Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Perez Marc, G.; Moreira, E.D.; Zerbini, C.; et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. [Google Scholar] [CrossRef]
- Sadoff, J.; Gray, G.; Vandebosch, A.; Cardenas, V.; Shukarev, G.; Grinsztejn, B.; Goepfert, P.A.; Truyers, C.; Fennema, H.; Spiessens, B.; et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N. Engl. J. Med. 2021, 384, 2187–2201. [Google Scholar] [CrossRef]
- Voysey, M.; Clemens, S.A.C.; Madhi, S.A.; Weckx, L.Y.; Folegatti, P.M.; Aley, P.K.; Angus, B.; Baillie, V.L.; Barnabas, S.L.; Bhorat, Q.E.; et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021, 397, 99–111. [Google Scholar] [CrossRef]
- Kamar, N.; Abravanel, F.; Marion, O.; Couat, C.; Izopet, J.; Del Bello, A. Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. N. Engl. J. Med. 2021, 385, 661–662. [Google Scholar] [CrossRef]
- Azzi, Y.; Bartash, R.; Scalea, J.; Loarte-Campos, P.; Akalin, E. COVID-19 and Solid Organ Transplantation: A Review Article. Transplantation 2021, 105, 37–55. [Google Scholar] [CrossRef]
- Holden, I.K.; Bistrup, C.; Nilsson, A.C.; Hansen, J.F.; Abazi, R.; Davidsen, J.R.; Poulsen, M.K.; Lindvig, S.O.; Justesen, U.S.; Johansen, I.S. Immunogenicity of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients. Online ahead of print. J. Intern. Med. 2021. [Google Scholar] [CrossRef] [PubMed]
- Marinaki, S.; Adamopoulos, S.; Degiannis, D.; Roussos, S.; Pavlopoulou, I.D.; Hatzakis, A.; Boletis, I.N. Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients. Am. J. Transplant. 2021, 21, 2913–2915. [Google Scholar] [CrossRef] [PubMed]
- Kennedy, N.A.; Lin, S.; Goodhand, J.R.; Chanchlani, N.; Hamilton, B.; Bewshea, C.; Nice, R.; Chee, D.; Cummings, J.F.; Fraser, A.; et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut 2021, 70, 1884–1893. [Google Scholar] [CrossRef] [PubMed]
- Wong, S.Y.; Dixon, R.; Martinez Pazos, V.; Gnjatic, S.; Colombel, J.F.; Cadwell, K.; Group, I.-I.W. Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies. Gastroenterology 2021, 161, 715–718.e4. [Google Scholar] [CrossRef]
- Kappelman, M.D.; Weaver, K.N.; Boccieri, M.; Firestine, A.; Zhang, X.; Long, M.D.; Group, P.-C.S. Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients with Inflammatory Bowel Disease. Gastroenterology 2021, 161, 1340–1343.e2. [Google Scholar] [CrossRef] [PubMed]
- Pozdnyakova, V.; Botwin, G.J.; Sobhani, K.; Prostko, J.; Braun, J.; McGovern, D.P.B.; Melmed, G.Y.; CORALE-IBD Study Group; Appel, K.; Banty, A.; et al. Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients with Inflammatory Bowel Disease. Gastroenterology 2021, in press. [Google Scholar] [CrossRef]
- Spencer, E.A.; Klang, E.; Dolinger, M.; Pittman, N.; Dubinsky, M.C. Seroconversion Following SARS-CoV-2 Infection or Vaccination in Pediatric IBD Patients. Inflamm. Bowel Dis. 2021, 27, 1862–1864. [Google Scholar] [CrossRef]
- Reuken, P.A.; Andreas, N.; Grunert, P.C.; Glockner, S.; Kamradt, T.; Stallmach, A. T cell response after SARS-CoV-2 vaccination in immunocompromised patients with inflammatory bowel disease. J. Crohn Colitis 2021, jjab147. [Google Scholar] [CrossRef]
- Botwin, G.J.; Li, D.; Figueiredo, J.; Cheng, S.; Braun, J.; McGovern, D.P.B.; Melmed, G.Y. Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients with Inflammatory Bowel Disease. Am. J. Gastroenterol. 2021, 116, 1746–1751. [Google Scholar] [CrossRef]
- Khan, N.; Mahmud, N. Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients with Inflammatory Bowel Disease with Diverse Exposure to Immunosuppressive Medications. Gastroenterology 2021, 161, 827–836. [Google Scholar] [CrossRef]
- Rahier, J.F.; Papay, P.; Salleron, J.; Sebastian, S.; Marzo, M.; Peyrin-Biroulet, L.; Garcia-Sanchez, V.; Fries, W.; van Asseldonk, D.P.; Farkas, K.; et al. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut 2011, 60, 456–462. [Google Scholar] [CrossRef] [PubMed]
- Machado, P.M.; Lawson-Tovey, S.; Hyrich, K.; Carmona, L.; Gossec, L.; Mateus, E.; Strangfeld, A.; Raffeiner, B.; Goulenok, T.; Brocq, O.; et al. LB0002 Covid-19 Vaccine Safety in Patients with Rheumatic and Musculoskeletal Disease. Ann. Rheum. Dis. 2021, 80, 199–200. [Google Scholar] [CrossRef]
- Pratt, P.K., Jr.; David, N.; Weber, H.C.; Little, F.F.; Kourkoumpetis, T.; Patts, G.J.; Weinberg, J.; Farraye, F.A. Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients with Inflammatory Bowel Disease on Infliximab Therapy. Inflamm. Bowel Dis. 2018, 24, 380–386. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cullen, G.; Bader, C.; Korzenik, J.R.; Sands, B.E. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut 2012, 61, 385–391. [Google Scholar] [CrossRef]
- Melmed, G.Y.; Agarwal, N.; Frenck, R.W.; Ippoliti, A.F.; Ibanez, P.; Papadakis, K.A.; Simpson, P.; Barolet-Garcia, C.; Ward, J.; Targan, S.R.; et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am. J. Gastroenterol. 2010, 105, 148–154. [Google Scholar] [CrossRef]
- Winthrop, K.L.; Silverfield, J.; Racewicz, A.; Neal, J.; Lee, E.B.; Hrycaj, P.; Gomez-Reino, J.; Soma, K.; Mebus, C.; Wilkinson, B.; et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann. Rheum. Dis. 2016, 75, 687–695. [Google Scholar] [CrossRef]
- Mazzola, A.; Todesco, E.; Drouin, S.; Hazan, F.; Marot, S.; Thabut, D.; Varnous, S.; Soulie, C.; Barrou, B.; Marcelin, A.G.; et al. Poor Antibody Response after Two Doses of SARS-CoV-2 vaccine in Transplant Recipients. Clin. Infect. Dis. 2021, ciab580. [Google Scholar] [CrossRef]
- Perry, C.; Luttwak, E.; Balaban, R.; Shefer, G.; Morales, M.M.; Aharon, A.; Tabib, Y.; Cohen, Y.C.; Benyamini, N.; Beyar-Katz, O.; et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv. 2021, 5, 3053–3061. [Google Scholar] [CrossRef]
- Alexander, J.L.; Moran, G.W.; Gaya, D.R.; Raine, T.; Hart, A.; Kennedy, N.A.; Lindsay, J.O.; MacDonald, J.; Segal, J.P.; Sebastian, S.; et al. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: A British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. Lancet Gastroenterol. Hepatol. 2021, 6, 218–224. [Google Scholar] [CrossRef]
- Kuenzig, M.E.; Bitton, A.; Carroll, M.W.; Kaplan, G.G.; Otley, A.R.; Singh, H.; Nguyen, G.C.; Griffiths, A.M.; Stukel, T.A.; Targownik, L.E.; et al. Inflammatory bowel disease increases the risk of venous thromboembolism in children: A population-based matched cohort study. J. Crohn Colitis 2021, jjab113. [Google Scholar] [CrossRef]
- McCurdy, J.D.; Ellen Kuenzig, M.; Spruin, S.; Fung, O.W.; Mallik, R.; Williams, L.; Murthy, S.K.; Carrier, M.; Nguyen, G.; Benchimol, E.I. Surgery and the Subtype of Inflammatory Bowel Disease Impact the Risk of Venous Thromboembolism After Hospital Discharge. Dig. Dis. Sci. 2021. [Google Scholar] [CrossRef] [PubMed]
- Bernstein, C.N.; Nugent, Z.; Singh, H. Persistently High Rate of Venous Thromboembolic Disease in Inflammatory Bowel Disease: A Population-Based Study. Am. J. Gastroenterol. 2021, 116, 1476–1484. [Google Scholar] [CrossRef] [PubMed]
- Greinacher, A.; Thiele, T.; Warkentin, T.E.; Weisser, K.; Kyrle, P.A.; Eichinger, S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N. Engl. J. Med. 2021, 384, 2092–2101. [Google Scholar] [CrossRef]
- Greinacher, A.; Langer, F.; Makris, M.; Pai, M.; Pavord, S.; Tran, H.; Warkentin, T.E. Vaccine-induced immune thrombotic thrombocytopenia (VITT)—Update on diagnosis and management considering different resources. J. Thromb. Haemost. 2021. ahead of print. [Google Scholar] [CrossRef] [PubMed]
Study | Study Cohort | Vaccines | Results |
---|---|---|---|
Kennedy et al. [23] | IBD patients with: Infliximab (n = 865) Vedolizumab (n = 428) | BNT162b2 ChAdOx1 |
|
Wong et al. [24] | IBD patients with: Anti-TNF-α (n = 16), Vedolizumab (n = 17) Vedolizumab/Thiopurin (n = 3) Ustekinumab (n = 4) oral Steroids (n = 3) No medication (n = 5) Healthy control subjects (n = 43) | mRNA-1273 BNT162b2 |
|
Kappelmann et al. [25] | IBD patients with: Anti-TNF-α (n = 108) Anti-TNF-α/Combination (n = 24) 6MP/AZA/MTX (n = 20) 5-ASA/Budesonide/no medication (n = 65) Vedolizumab (n = 46) Ustekinumab (n = 39) | BNT162b2 mRNA-1273 |
|
Pozdnyakova et al. [26] | IBD patients with: Anti-TNF (n = 101) Anti-TNF-α/Combination (n = 32) 6MP/AZA/MTX (n = 20) 5-ASA/Budesonide/no medication (n = 65) Vedolizumab (n = 49) Ustekinumab (n = 94) Tofacitinib (n = 6) | BNT162b2 (2 doses, n = 193) mRNA-1273 (2 doses, n = 148) Ad26.CoV2.S (n = 12) |
|
Spencer et al. [27] | IBD patients with: Anti-TNF-α (n = 9) Ustekinumab (n = 9) Ustekinumab/Tofacitinib (n = 1) Tofacitinib (n = 1) | Ad26.CoV2.S mRNA-1273 BNT162b2 |
|
Reuken et al. [28] | IBD patients with: Steroids (n = 2) Anti-TNF-α (n = 9) Vedolizumab (n = 3) Ustekinumab (n = 8) Azathioprin (n = 3) Mycophenolate (n = 2) Tacrolimus (n = 3) Tofacitinib (n = 1) Healthy controls (n = 27) | BNT162b2 ChAdOx1 |
|
Botwin et al. [29] | 246 vaccinated IBD patients with different immunomodulating therapies | mRNA-1273 BNT162b2 |
|
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tepasse, P.-R.; Vollenberg, R.; Nowacki, T.M. Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand? Life 2021, 11, 1220. https://doi.org/10.3390/life11111220
Tepasse P-R, Vollenberg R, Nowacki TM. Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand? Life. 2021; 11(11):1220. https://doi.org/10.3390/life11111220
Chicago/Turabian StyleTepasse, Phil-Robin, Richard Vollenberg, and Tobias Max Nowacki. 2021. "Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand?" Life 11, no. 11: 1220. https://doi.org/10.3390/life11111220